Companies Cryptocurrencies
Immunovant Inc
Immunovant Inc
Exchange: NasdaqCM
IPO Date: 10/05/2019
CEO: Dr. Peter Salzmann M.B.A., M.D.
Biotechnology Healthcare 🔗
  • IMVT
  • 5.62
  • 655162752
    market cap
  • 0.32999992
If you bought

shares of Immunovant Inc (IMVT) on
You would have made
Old Price $12 Current Price $12

Immunovant, Inc., formerly Health Sciences Acquisitions Corp, is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. It is developing IMVT-1401, a human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. IMVT-1401 is being developed to target the neonatal Fc receptor (FcRn).

Address: 320 West 37Th Street New York City NEW YORK 10018

Stay updated.